Anlon Healthcare

Which are the latest news on Anlon Healthcare?

Why is Anlon Healthcare Ltd falling/rising?

As of 05-Sep, Anlon Healthcare Ltd's stock price is rising at 15.68, reflecting strong recent performance with a 7.62% growth over the past month and a 71.18% increase over the last year, despite a decline in investor participation. The company's solid financial health is underscored by a low Debt to EBITDA ratio and significant annual sales growth.

As of 05-Sep, Anlon Healthcare Ltd's stock price is rising, currently at 15.68, with a change of 0.08 (0.51%) upwards. The stock has shown a strong performance recently, having outperformed its sector by 1.41% today and achieving consecutive gains for the last three days, resulting in a total increase of 1.55% during this period. Additionally, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend.<BR><BR>Over the past month, Anlon Healthcare has demonstrated significant growth, with a return of 7.62%, contrasting with a decline of 2.44% in the benchmark index. Year-to-date, the stock has increased by 3.57%, while the broader market has decreased by 10.21%. Furthermore, the stock has generated an impressive return of 71.18% over the last year, significantly outperforming the market's return of just 1.51%.<BR><BR>Despite some concerns regarding falling investor participation, as evidenced by a 17.22% decrease in delivery volume compared to the 5-day average, the overall financial health of the company remains strong. Anlon Healthcare has a low Debt to EBITDA ratio of 1.81 times, indicating a strong ability to service its debt. The company has also experienced healthy long-term growth, with net sales increasing at an annual rate of 65.60%.<BR><BR>In summary, the combination of recent positive performance, strong growth metrics, and a solid financial position contributes to the rising stock price of Anlon Healthcare Ltd.

Should I buy, sell or hold Anlon Healthcare Ltd?

What does Anlon Healthcare do?

Anlon Healthcare Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 88 Cr and a net profit of 7 Cr for June 2026. Key metrics include a P/E ratio of 32.00 and a market cap of INR 832 Cr.

Overview: <BR>Anlon Healthcare Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>The incorporation year and any status changes are not available. The latest quarter for which sales and profit are reported is June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 88 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 7 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 832 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 32.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.20 <BR>Return on Equity: 13.85% <BR>Price-to-Book: 4.04<BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Anlon Healthcare?

Anlon Healthcare's peers include Kopran, Bharat Parenter, Wanbury, Anuh Pharma, Shree Ganesh Rem, Bafna Pharma, Amanta Healthcare, Zim Laboratories, and Influx Health. In terms of management risk, Anlon Healthcare has an average rating, while it shows excellent growth; Bafna Pharma has the highest 1-year return at 198.53%, and Wanbury has the lowest at -8.90%.

Peers: The peers of Anlon Healthcare are Kopran, Bharat Parenter., Wanbury, Anuh Pharma, Shree Ganesh Rem, Bafna Pharma., Amanta Healthcar, Zim Laboratories, Influx Health.<BR><BR>Quality Snapshot: Excellent management risk is observed at Anuh Pharma and Influx Health., while Average management risk is found at Kopran, Wanbury, Anlon Healthcare, Shree Ganesh Rem, Amanta Healthcar, Zim Laboratories, and the rest. Below Average management risk is seen at Bharat Parenter. and Bafna Pharma. In terms of Growth, Excellent growth is noted at Anlon Healthcare, while Average growth is observed at Wanbury and Influx Health., and the rest show Below Average growth. For Capital Structure, Excellent capital structure is found at Anuh Pharma and Shree Ganesh Rem, Good at Anlon Healthcare and Kopran, while Below Average is noted at Bharat Parenter. and Amanta Healthcar, and Average at Bafna Pharma. and Zim Laboratories.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bafna Pharma. at 198.53%, while Wanbury has the lowest at -8.90%. Anlon Healthcare does not have a 1-year return available for comparison. Additionally, peers with negative six-month returns include Wanbury and Anuh Pharma.

How big is Anlon Healthcare?

As of 31st August, Anlon Healthcare Ltd has a market capitalization of 832.00 Cr and reported net sales of 207.33 Cr and net profit of 25.86 Cr over the latest four quarters.

As of 31st August, <BR><BR>Market Cap: Anlon Healthcare Ltd has a market capitalization of 832.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 207.33 Cr, while the sum of Net Profit for the same period is 25.86 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2026, with Shareholder's Funds amounting to 230.23 Cr and Total Assets totaling 373.97 Cr.

Are Anlon Healthcare Ltd latest results good or bad?

Anlon Healthcare Ltd's latest results show strong revenue growth of 78.95% year-on-year, reaching ₹87.56 crores, but a concerning 60% decline in net profit to ₹6.66 crores and significantly reduced margins indicate underlying operational challenges. Investors should be cautious due to these profitability concerns despite the revenue increase.

Anlon Healthcare Ltd's latest results present a mixed picture, leaning towards the negative due to significant profitability concerns despite impressive revenue growth. In Q1 FY27, the company reported a net profit of ₹6.66 crores, which is a substantial decline of 60% year-on-year and a 36.57% drop compared to the previous quarter. This decline in profitability is alarming, especially given the backdrop of a strong revenue increase of 78.95% year-on-year, reaching ₹87.56 crores.<BR><BR>While the revenue growth indicates successful market penetration or new product launches, it came at the cost of severely compressed margins. The operating margin fell dramatically from 30.05% in the previous quarter to 17.80%, and the PAT margin also decreased significantly to 9.46%. This suggests that the company may be facing increased costs or adopting aggressive pricing strategies to gain market share, which raises questions about the sustainability of this growth.<BR><BR>Overall, while Anlon Healthcare has demonstrated strong revenue growth, the substantial decline in profitability and margins indicates underlying operational challenges that need to be addressed. Investors should approach the company's performance with caution, given the current financial dynamics.

When is the next results date for Anlon Healthcare Ltd?

The next results date for Anlon Healthcare Ltd is 30 July 2026.

The next results date for Anlon Healthcare Ltd is scheduled for 30 July 2026.